Cancer Genetics, Inc. announces appointment of Randy Goodman, Ph.D. as Director of Reimbursement and Clinical Revenue Cycle Management.
Cancer Genetics, Inc. announces that it has begun testing for two clinical trials focused on diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). The total value of the contracts is expected to exceed $2.5 million USD.
Cancer Genetics announces the launch of their ExpandDx™ collaborative testing program. The technical-only testing service provides community hospitals and pathology labs with the most advanced testing technologies available, and facilitates increased collaboration on both atypical and difficult cancer cases.
Cancer Genetics, Inc. announced today that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License will allow the company to provide its state-of-the art oncology testing services for patient samples from the state of California.
Cancer Genetics, Inc. announces the addition of Venkatadri Bobba to Cancer Genetics India’s Board of Directors.
Cancer Genetics, Inc. announced today that Rob Fannon has joined the company as vice president of operations in the Raleigh/Research Triangle Park (RTP), North Carolina location. Fannon, previously with Roche Molecular’s BioSpecimen Management division, brings more than 10 years of operations, client management, molecular test and panel development, and biorepository management experience to CGI.
Cancer Genetics, Inc. announced today that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.
Cancer Genetics, Inc., announces launch of next-generation sequencing (NGS) based panel for chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Focus::CLL™ is the only NGS panel to assess seven biomarkers with clinical utility for prognosis and treatment selection of CLL/SLL.
Cancer Genetics, Inc.announced today the addition of Howard McLeod, Pharm. D., and Geoffrey Harris to the Company’s Board of Directors.
Cancer Genetics, Inc. announced today that it will present at the 26th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 2, 2014. Representatives from the company will speak at 8:10 am EST.
Cancer Genetics, Inc. announced today that it will present two posters on diffuse large B-cell lymphoma (DLBCL) at the 56th annual meeting of the American Society of Hematology (ASH), in San Francisco, CA. A third poster on multiple myeloma (MM) will be presented by OncoSpire Genomics, CGI’s joint venture with Mayo Clinic.
Cancer Genetics, Inc. announced it ranked 303 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. CGI grew 296% percent as measured by revenues during this period.
CGI to present at Canaccord Genuity Medical Technology and Diagnostics Conference in New York on Thursday, November 20, 2014.
RUTHERFORD, N.J., Nov. 12, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today that it will present on its next generation sequencing (NGS) panels for hematological malignancies at the Association for Molecular Pathology’s (AMP) 2014 Annual Meeting in Harbor, MD. Principal clinical scientist […]
CGI receives second US patent covering proprietary FISH-based HPV-Associated Cancer Test (FHACT®) for cervical cancer detection in patients.
CGI announces financial and operating results for the third quarter 2014. Third quarter revenue of $3.22 million represents revenue growth of ~90% over same quarter 2013, including 159% revenue growth in biopharma services and 44% growth in clinical services.
Issuance of patent 8,865,882 covers four probe set used in CGI’s proprietary FISH-based HPV-Associated Cancer Test (FHACT®) >FHACT® cervical cancer detection test has potential application for more than 2 million patients per year in the United States RUTHERFORD, N.J., Oct. 21, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging […]
The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Nearly 100,000 people are living with MDS in the US, and both MDS and AML are increasing globally in incidence and prevalence. According to the National Cancer Institute, the […]
RUTHERFORD, N.J., Oct. 30, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern […]
RUTHERFORD, N.J. and RALEIGH, N.C., Sept. 24, 2014 (GLOBE NEWSWIRE) — Cancer Genetics Inc.(Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina. The event will offer updated information on the Company’s portfolio of […]